Janssen-Cilag Ltd: UK Public Sector Contracts Won & Awards

Large organisationCompanies House: Private Limited CompanyHigh WycombeSouth East EnglandMain market: Pharmaceutical products

Official UK PPONPTBW-9923-RLZDCompanies House01027904 ↗ · Active

Where they win
i

87 awards (84 for a named lot, 97%, 3 for a whole procedure with no lot named) · top CPV classes, shares of all 87 awards. An award may cover more than one class.

3360 Pharmaceutical products87 awards · 100% · 84 awards naming a lot + 3 whole-procedure awards
Attributable award value
i
£555kOn 1 of 87 award records; the five largest make 100%. Largest rows below.
Largest published awards
i
AuthorityAwardedTermPublished value
Biologic and Biosimilar MedicineseTenderwales——£555,400 †

Where their buyers are
i

ITL1 region of the buyer office · known for 67 of 67 awarded procedures · each procedure counts once

Greater London42 procedures · 63%
Scotland14 procedures · 21%
North West England5 procedures · 7%
Northern Ireland3 procedures · 4%
Wales (Cymru)2 procedures · 3%
South East England1 procedure · 1%

Bidding record
i

Procurement Act 2023 award notices name every bidder · 6 notices name this supplier, covering 8 lots since 17 Oct 2025 · observed bids, not an estimate

Contract lots contested
i
0 won · 0 lostFewer than three decided lots: no rate is claimed.
Framework / DPS places
i
5 of 8Lots on 6 notices: a place is won per lot.
Authorities bid for
i
1
NoticeAuthorityOutcomeBiddersPublished
NHS National Generic Pharmaceuticals - Wave 16aframework/DPSNHS Englandnot appointed1259 Oct 2026
NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026framework/DPSNHS Englandappointedall 2 lots bid for2610 Jul 2026
NHS National Generics Pharmaceuticals - Supply Chain Resilienceframework/DPSNHS Englandappointed416 Jul 2026
NHS National Branded Interim - 1 June 2026framework/DPSNHS Englandappointed5322 May 2026
NHS National Generic Pharmaceuticals - Wave 15cframework/DPSNHS Englandnot appointed11826 Feb 2026
NHS National Framework for Golimumab Injectionframework/DPSNHS Englandappointed317 Oct 2025

Bidder names come from Procurement Act 2023 award notices, which list every bidder (from 2025). Older notices name no bidders, so earlier contests do not appear here. Latest ten notices shown.

Who they sell to
i

Authorities named on this supplier’s published awards · ranked by distinct procedures · a framework or DPS adds one award record per appointed supplier

Authority type · official UK type when published, else name/id class, else not classified · by award records (a single panel can dominate)
i
  • NHS & health85%(74 awards)
    74 of 87 awards are NHS & health (85%).
  • Type not classified15%(13 awards)
    13 of 87 awards are Type not classified (15%).
AuthorityProceduresShareAward recordsLast activity
NHS Englandframework/DPS on 364262.7%636 Jul 2026
The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")framework/DPS on 141420.9%2218 Jul 2026
The NHS Commissioning Board (operating under the name of NHS England)framework/DPS on 557.5%77 Feb 2022
Business Services Organisation Procurement and Logistics Serviceframework/DPS on 334.5%919 Aug 2025
eTenderwales11.5%123 Apr 2025
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)11.5%125 Nov 2025
ATAMIS LTD11.5%17 Jul 2023

Share = of the 67 procedures with an award naming this supplier. Last activity = award date, or notice publication when no award date was published.

Contracts ending
i

85 of 104 awards carry an end date, 21 estimated from the duration · not a retender forecast

ContractEndsPublished value
Infliximab IV19 Jan 2027 estimated£44,300,000 ceiling
NP49425 Generic and Biosimilar Transition Medicines28 Feb 2027£64,103,740 ceiling
Cytokine Modulators (Golimumab, Tocilizumab, and Etanercept)28 Feb 2027£26,539,272 ceiling
NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)31 May 2027Not published
Wave 14c - Orals (plus non-parenteral) Products (all regions)31 May 2027£1 ceiling
Medicinal Products - Direct to Trust2 Jun 2027 estimated£210,000,000 ceiling
Medicinal Products - with Pharma Funded Homecare Services2 Jun 2027 estimated£174,000,000 ceiling
NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 202531 Aug 2027£986,282,758
NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National31 Aug 2027£261,895,933
Lot 2 - CM/PHR/25/5731/02 - Ustekinumab NOFE & MAE31 Aug 2027£18,903,212 ceiling

Soonest 10 of 15.

Recent awards

Latest 30 of 87 award records naming this supplier

Other official notice feeds add 17 more procedures won by this supplier. Each is counted once beside any Find a Tender copy; they are in the totals, not in this list.

Award / procedureAuthorityAwardedPublished value
Generic, Branded Generic & Proprietary Medicinal Products - Group 18Business Services Organisation Procurement and Logistics ServiceNot published£6,403,383 †
dynamic market estimate · not attributable revenue
Generic, Branded Generic & Proprietary Medicinal Products - Group 18Business Services Organisation Procurement and Logistics ServiceNot published£21,200 †
dynamic market estimate · not attributable revenue
Generic, Branded Generic & Proprietary Medicinal Products - Group 18Business Services Organisation Procurement and Logistics ServiceNot published£6,720,719 †
dynamic market estimate · not attributable revenue
Generic HIV MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£3,636,988 †
framework ceiling · 1 of 10 appointed suppliers
Branded HIV MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£79,068,428 †
framework ceiling · 1 of 5 appointed suppliers
NP49425 Generic and Biosimilar Transition MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£64,103,740 †
framework ceiling · 1 of 31 appointed suppliers
Cytokine Modulators (Golimumab, Tocilizumab, and Etanercept)The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£26,539,272 †
framework ceiling · 1 of 5 appointed suppliers
NHS National Framework for Golimumab InjectionNHS EnglandNot published£60,000,000 †
framework ceiling · 1 of 3 appointed suppliers
Carbamazepine, lamotrigine, levodopa / carbidopa / entacapone, methylphenidate, phenytoin sodium, sodium valproate, and valproic acidThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£281,820 †
framework ceiling · 1 of 17 appointed suppliers
All other psychiatry and neurology medicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")Not published£6,750,119 †
framework ceiling · 1 of 33 appointed suppliers
About this data
  • One profile per supplier. Built from award and contract notices that name this supplier; different spellings and registration numbers of the same company are merged into this profile.
  • Values are published values. The table mirrors what the notice published: framework ceilings and joint awards are labelled and never counted as this supplier's money, and † marks a value taken from the contract notice when the award published none. Only awards made to this supplier alone count towards its value, excluding VAT. It is not turnover.
  • Regions in the buyer chart describe the buyer office, not where the work is delivered or the supplier’s registered address.
  • Contract end dates. Published on 64 of 104 awards, estimated from the published duration on 21 more (marked “estimated”); those feed “Contracts ending”. Published values in that list come from either source; Contracts Finder figures are shown as published and stay out of this profile’s money totals.
  • Source. Official UK public procurement notices (Find a Tender, Contracts Finder and Public Contracts Scotland), reused under the Open Government Licence v3.0, updated through the day and rebuilt nightly. Not every figure uses every feed, and each one shows how many records it rests on: see the methodology. Spotted something wrong? Tell us.